

Jagpreet Chhatwal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1792682/publications.pdf>

Version: 2024-02-01

106
papers

3,833
citations

126858

33
h-index

143943

57
g-index

114
all docs

114
docs citations

114
times ranked

5657
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States. <i>Annals of Internal Medicine</i> , 2015, 162, 397-406.	2.0	303
2	Prevention of Prescription Opioid Misuse and Projected Overdose Deaths in the United States. <i>JAMA Network Open</i> , 2019, 2, e187621.	2.8	220
3	Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons. <i>Annals of Internal Medicine</i> , 2016, 164, 84.	2.0	137
4	Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. <i>Journal of Clinical Oncology</i> , 2017, 35, 166-174.	0.8	131
5	The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions. <i>Annals of Internal Medicine</i> , 2014, 161, 170.	2.0	129
6	Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals. <i>Hepatology</i> , 2016, 64, 1442-1450.	3.6	126
7	Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoteric acid. <i>Abdominal Radiology</i> , 2017, 42, 179-190.	1.0	113
8	Oral Human Papillomavirus Infection: Differences in Prevalence Between Sexes and Concordance With Genital Human Papillomavirus Infection, NHANES 2011 to 2014. <i>Annals of Internal Medicine</i> , 2017, 167, 714.	2.0	112
9	Optimal Breast Biopsy Decision-Making Based on Mammographic Features and Demographic Factors. <i>Operations Research</i> , 2010, 58, 1577-1591.	1.2	94
10	Projected prevalence and mortality associated with alcohol-related liver disease in the USA, 2019-2040: a modelling study. <i>Lancet Public Health</i> , The, 2020, 5, e316-e323.	4.7	87
11	Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. <i>Hepatology</i> , 2017, 65, 777-788.	3.6	83
12	Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 827-837.e8.	2.4	81
13	Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India. <i>PLoS ONE</i> , 2017, 12, e0176503.	1.1	79
14	Bariatric surgery for nonalcoholic steatohepatitis: A clinical and cost-effectiveness analysis. <i>Hepatology</i> , 2017, 65, 1156-1164.	3.6	76
15	A clash of epidemics: Impact of the COVID-19 pandemic response on opioid overdose. <i>Journal of Substance Abuse Treatment</i> , 2021, 120, 108158.	1.5	76
16	Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals. <i>Pharmacoeconomics</i> , 2016, 34, 551-567.	1.7	74
17	Clinical Impact of Alcohol-Related Cirrhosis in the Next Decade: Estimates Based on Current Epidemiological Trends in the United States. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 2085-2094.	1.4	70
18	Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis. <i>Hepatology</i> , 2017, 65, 920-928.	3.6	70

#	ARTICLE	IF	CITATIONS
19	Effect of increased alcohol consumption during COVID-19 pandemic on alcohol-associated liver disease: A modeling study. <i>Hepatology</i> , 2022, 75, 1480-1490.	3.6	69
20	Hepatitis C: The beginning of the end—key elements for successful European and national strategies to eliminate HCV in Europe. <i>Journal of Viral Hepatitis</i> , 2018, 25, 6-17.	1.0	65
21	Cost-Effectiveness of Boceprevir in Patients Previously Treated for Chronic Hepatitis C Genotype 1 Infection in the United States. <i>Value in Health</i> , 2013, 16, 973-986.	0.1	63
22	Cost-effectiveness of Bariatric Surgery in Adolescents With Obesity. <i>JAMA Surgery</i> , 2017, 152, 136.	2.2	62
23	Should we treat acute hepatitis C? A decision and cost-effectiveness analysis. <i>Hepatology</i> , 2018, 67, 837-846.	3.6	61
24	Trends in Risks for Second Primary Cancers Associated With Index Human Papillomavirus-Associated Cancers. <i>JAMA Network Open</i> , 2018, 1, e181999.	2.8	54
25	Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2&6. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 711-721.	1.9	52
26	Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: A modeling study. <i>Hepatology</i> , 2018, 67, 2085-2095.	3.6	50
27	Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. <i>BMC Infectious Diseases</i> , 2013, 13, 190.	1.3	48
28	Are high drug prices for hematologic malignancies justified? A critical analysis. <i>Cancer</i> , 2015, 121, 3372-3379.	2.0	43
29	Cost-effectiveness Analysis of Bariatric Surgery for Patients With Nonalcoholic Steatohepatitis Cirrhosis. <i>JAMA Network Open</i> , 2019, 2, e190047.	2.8	42
30	Long-Term Outcomes of Adding HPV Vaccine to the Anal Intraepithelial Neoplasia Treatment Regimen in HIV-Positive Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2015, 61, 1527-1535.	2.9	41
31	Model to Calculate Harms and Benefits of Early vs Delayed Liver Transplantation for Patients With Alcohol-Associated Hepatitis. <i>Gastroenterology</i> , 2019, 157, 472-480.e5.	0.6	39
32	Economic Evaluations with Agent-Based Modelling: An Introduction. <i>Pharmacoeconomics</i> , 2015, 33, 423-433.	1.7	38
33	Changing Cycle Lengths in State-Transition Models. <i>Medical Decision Making</i> , 2016, 36, 952-964.	1.2	38
34	The impact of direct-acting anti-virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 66-74.	1.9	37
35	Incidence Trends and Burden of Human Papillomavirus-Associated Cancers Among Women in the United States, 2001-2017. <i>Journal of the National Cancer Institute</i> , 2021, 113, 792-796.	3.0	35
36	Cost-Effectiveness Analysis of Boceprevir for the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection in Portugal. <i>Applied Health Economics and Health Policy</i> , 2013, 11, 65-78.	1.0	34

#	ARTICLE	IF	CITATIONS
37	Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study. <i>BMJ Open</i> , 2019, 9, e026726.	0.8	34
38	Assessment of the Feasibility and Cost of Hepatitis C Elimination in Pakistan. <i>JAMA Network Open</i> , 2019, 2, e193613.	2.8	32
39	Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir <i>versus</i> genotype-dependent direct-acting antivirals for hepatitis C treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 2029-2036.	1.4	31
40	Management of precancerous anal intraepithelial lesions in human immunodeficiency virus-positive men who have sex with men: Clinical effectiveness and cost-effectiveness. <i>Cancer</i> , 2017, 123, 4709-4719.	2.0	29
41	Trends in Thyroid Surgery and Guideline-Concordant Care in the United States, 2007-2018. <i>Thyroid</i> , 2021, 31, 941-949.	2.4	28
42	From Data to Improved Decisions: Operations Research in Healthcare Delivery. <i>Medical Decision Making</i> , 2017, 37, 849-859.	1.2	25
43	Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1023-1031.	1.9	25
44	Reduction of COVID-19 Incidence and Nonpharmacologic Interventions: Analysis Using a US County-Level Policy Data Set. <i>Journal of Medical Internet Research</i> , 2020, 22, e24614.	2.1	25
45	Long-term impact of HPV vaccination and COVID-19 pandemic on oropharyngeal cancer incidence and burden among men in the USA: A modeling study. <i>The Lancet Regional Health Americas</i> , 2022, 8, 100143.	1.5	25
46	Cost Effectiveness of Transplanting HCV-Infected Livers Into Uninfected Recipients With Preemptive Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 739-747.e8.	2.4	24
47	Securing sustainable funding for viral hepatitis elimination plans. <i>Liver International</i> , 2020, 40, 260-270.	1.9	24
48	Theoretical Foundations and Practical Applications of Within-Cycle Correction Methods. <i>Medical Decision Making</i> , 2016, 36, 115-131.	1.2	23
49	Hep C Calculator: an online tool for cost-effectiveness analysis of DAAs. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 819.	3.7	23
50	Prevalence of Human Papillomavirus Infection by Number of Vaccine Doses Among US Women. <i>JAMA Network Open</i> , 2019, 2, e1918571.	2.8	23
51	Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 115-122.e10.	2.4	21
52	Prioritizing Hepatitis C Treatment in U.S. Prisons. <i>Operations Research</i> , 2019, 67, 853-873.	1.2	21
53	Adjuvant HPV vaccination for anal cancer prevention in HIV-positive men who have sex with men: The time is now. <i>Vaccine</i> , 2017, 35, 5102-5109.	1.7	20
54	Five Questions Concerning Managing Hepatitis C in the Justice System. <i>Infectious Disease Clinics of North America</i> , 2018, 32, 323-345.	1.9	19

#	ARTICLE	IF	CITATIONS
55	Why should we apply ABM for decision analysis for infectious diseases? An example for dengue interventions. PLoS ONE, 2019, 14, e0221564.	1.1	19
56	Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication. Journal of Hepatology, 2022, 77, 55-62.	1.8	19
57	Myths and Misconceptions of Within-Cycle Correction: A Guide for Modelers and Decision Makers. Pharmacoeconomics, 2016, 34, 13-22.	1.7	18
58	The Association Between Dietary Quality and Overall and Cancer-Specific Mortality Among Cancer Survivors, NHANES III. JNCI Cancer Spectrum, 2018, 2, pky022.	1.4	18
59	Optimal <i>M</i> -Switch Surveillance Policies for Liver Cancer in a Hepatitis C-Infected Population. Operations Research, 2018, 66, 673-696.	1.2	18
60	Improved Health Outcomes from Hepatitis C Treatment Scale-Up in Spain's Prisons: A Cost-Effectiveness Study. Scientific Reports, 2019, 9, 16849.	1.6	17
61	Universal Screening for Hepatitis C: An Important Step in Virus Elimination. Clinical Gastroenterology and Hepatology, 2019, 17, 835-837.	2.4	16
62	Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income. Value in Health, 2020, 23, 1552-1560.	0.1	16
63	Projecting COVID-19 Mortality as States Relax Nonpharmacologic Interventions. JAMA Health Forum, 2022, 3, e220760.	1.0	16
64	Estimation of Hepatitis C Disease Burden and Budget Impact of Treatment Using Health Economic Modeling. Infectious Disease Clinics of North America, 2018, 32, 461-480.	1.9	15
65	Assessment of Incidence of and Surveillance Burden for Hepatocellular Carcinoma Among Patients With Hepatitis C in the Era of Direct-Acting Antiviral Agents. JAMA Network Open, 2020, 3, e2021173.	2.8	15
66	Sensitivity Analysis in Sequential Decision Models. Medical Decision Making, 2017, 37, 243-252.	1.2	13
67	Hepatitis C Screening: From Modeling to Public Health Policy. Clinical Infectious Diseases, 2018, 66, 385-386.	2.9	11
68	Why We Should Be Willing to Pay for Hepatitis C Treatment. Clinical Gastroenterology and Hepatology, 2015, 13, 1711-1713.	2.4	10
69	Funding Hepatitis C Treatment in Correctional Facilities by Using a Nominal Pricing Mechanism. Journal of Correctional Health Care, 2019, 25, 15-24.	0.2	10
70	Diagnostic Accuracy of Shear Wave Elastography as a Non-invasive Biomarker of High-Risk Non-alcoholic Steatohepatitis in Patients with Non-alcoholic Fatty Liver Disease. Ultrasound in Medicine and Biology, 2020, 46, 972-980.	0.7	10
71	Estimating the price at which hepatitis C treatment with direct-acting antivirals would be cost-saving in Japan. Scientific Reports, 2020, 10, 4089.	1.6	9
72	Health economic design for cost, cost-effectiveness and simulation analyses in the HEALing Communities Study. Drug and Alcohol Dependence, 2020, 217, 108336.	1.6	8

#	ARTICLE	IF	CITATIONS
73	Association of Limited In-Person Attendance in US National Football League and National Collegiate Athletic Association Games With County-Level COVID-19 Cases. <i>JAMA Network Open</i> , 2021, 4, e2119621.	2.8	7
74	Budget Impact Analysis of Cancer Screening: A Methodological Review. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 493-511.	1.0	6
75	Assessing the impact of simplified HCV care on linkage to care amongst high-risk patients at primary healthcare clinics in Malaysia: a prospective observational study. <i>BMJ Open</i> , 2021, 11, e055142.	0.8	6
76	Long-term disease and economic outcomes of prior authorization criteria for Hepatitis C treatment in Pennsylvania Medicaid. <i>Healthcare</i> , 2017, 5, 105-111.	0.6	5
77	Changing Epidemiology of Hepatocellular Carcinoma and Role of Surveillance. <i>Molecular and Translational Medicine</i> , 2019, , 53-67.	0.4	5
78	Assessing cost-effectiveness of hepatitis C testing pathways in Georgia using the Hep C Testing Calculator. <i>Scientific Reports</i> , 2021, 11, 21382.	1.6	5
79	Letter to the Editor: Hepatitis C Virus Prevalence Estimates Among Incarcerated Persons. <i>Hepatology</i> , 2019, 70, 758-759.	3.6	4
80	Folic Acid-Containing Dietary Supplement Consumption and Risk of Cardiovascular Diseases in Rheumatoid Arthritis Patients: NHANES 1999â€“2014. <i>Journal of General Internal Medicine</i> , 2019, 34, 15-16.	1.3	4
81	Patient and Provider Risk in Managing ST-Elevation Myocardial Infarction During the COVID-19 Pandemic. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e010027.	1.4	4
82	A Tool to Inform Hepatitis C Elimination: A Case for Hepatitis C Elimination in China. <i>Clinical Liver Disease</i> , 2021, 17, 99-106.	1.0	4
83	Comparative Effectiveness of Implantable Defibrillators for Asymptomatic Brugada Syndrome: A Decisionâ€“Analytic Model. <i>Journal of the American Heart Association</i> , 2021, 10, e021144.	1.6	4
84	Comparative Clinical Effectiveness of Populationâ€“Based Atrial Fibrillation Screening Using Contemporary Modalities: A Decisionâ€“Analytic Model. <i>Journal of the American Heart Association</i> , 2021, 10, e020330.	1.6	4
85	Feasibility, effectiveness and cost of a decentralized HCV care model among the general population in Delhi, India. <i>Liver International</i> , 2021, , .	1.9	4
86	Nonalcoholic Fatty Liver Disease Natural History: Role of Mathematical Modeling. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 280-282.	2.4	4
87	Cost-effectiveness and Decision Analysis in Clinical Gastroenterology and Hepatology: From Evidence to Informed Decision Making. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 459-461.	2.4	3
88	Cost-Effectiveness of Remdesivir for COVID-19 Treatment: What Are We Missing?. <i>Value in Health</i> , 2022, , .	0.1	3
89	COVID-19 Health Economics: Looking Back and Scoping the Future. <i>Value in Health</i> , 2022, 25, 695-696.	0.1	3
90	Alternative Conversion Methods for Transition Probabilities in State-Transition Models: Validity and Impact on Comparative Effectiveness and Cost-Effectiveness. <i>Medical Decision Making</i> , 2019, 39, 509-522.	1.2	2

#	ARTICLE	IF	CITATIONS
91	Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary. <i>Journal of Health Economics and Outcomes Research</i> , 2013, 1, 62-82.	0.6	2
92	Reply to C. Nabhan et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 1864-1865.	0.8	1
93	Reply. <i>Hepatology</i> , 2018, 67, 1641-1642.	3.6	1
94	We are Not Meeting the Needs of Pharmacoeconomic Models of Nonalcoholic Steatohepatitis, But We Can. <i>Pharmacoeconomics</i> , 2020, 38, 427-429.	1.7	1
95	Health Economics of Interventions to Tackle the Coronavirus 2019 Pandemic. <i>Value in Health</i> , 2021, 24, 605-606.	0.1	1
96	Multi-target blood test to improve the performance of hepatocellular carcinoma surveillance programs: A modeling-based virtual trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 405-405.	0.8	1
97	Cost-Effectiveness of a Core Antigen-Based Rapid Diagnostic Test for Hepatitis C. <i>Value in Health</i> , 2022, , .	0.1	1
98	Productivity losses under various second-line recurrent or metastatic cervical cancer treatment scenarios in the United States.. <i>Journal of Clinical Oncology</i> , 2022, 40, e17520-e17520.	0.8	1
99	Acceptance of Surgical Treatment for Adolescent Obesity-Reply. <i>JAMA Surgery</i> , 2017, 152, 802.	2.2	0
100	Reply. <i>Hepatology</i> , 2017, 66, 1005-1006.	3.6	0
101	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1981.	2.4	0
102	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1815.	2.4	0
103	Reply. <i>Hepatology</i> , 2018, 68, 793-793.	3.6	0
104	Reply to L. Yaghjyan et al.. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky046.	1.4	0
105	Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5532-5532.	0.8	0
106	Cervical cancer geographical burden analyzer: An interactive, open-access tool for understanding geographical disease burden in patients with recurrent or metastatic cervical cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5523-5523.	0.8	0